Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.51 |
| ▸ | AKT2 | P31751 | 1/20 | 0.51 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 19/20 | 0.43 |
| ▸ | RPS6KA1 | Q15418 | 3/20 | 0.43 |
| ▸ | CDK2 | P24941 | 14/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 10/20 | 0.41 |
| ▸ | MAPK3 | P27361 | 10/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL681699 | 0.90 | AKT1 (0.41) | AKT1AKT2AKT3 | |
| SCHEMBL681234 | 0.90 | AKT1 (0.41) | AKT1AKT2AKT3MAPK1CDK2 | |
| SCHEMBL681441 | 0.89 | AKT1 (0.53) | AKT1AKT2AKT3MAPK1RPS6KA1 | |
| SCHEMBL17803804 | 0.88 | ALDH1A1 (0.40) | AKT1AKT2AKT3MAPK1RPS6KA1 | |
| SCHEMBL681770 | 0.87 | AKT1 (0.40) | AKT1AKT2AKT3MAPK1RPS6KA1 | |
| SCHEMBL12194528 | 0.87 | AKT1 (0.40) | AKT1AKT2AKT3MAPK1RPS6KA1 | |
| SCHEMBL12188392 | 0.87 | AKT1 (0.54) | AKT1AKT2AKT3MAPK1RPS6KA1 | |
| SCHEMBL681588 | 0.85 | MAPK1 (0.39) | AKT1AKT2AKT3MAPK1 | |
| SCHEMBL17803805 | 0.85 | MAPK1 (0.43) | AKT1AKT2AKT3MAPK1RPS6KA1 | |
| SCHEMBL2738961 | 0.84 | AKT1 (0.52) | AKT1AKT2AKT3MAPK1RPS6KA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359340-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-8846681-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8063050-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110245230-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245230-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | AKT1 3/4885AKT2 4/4885AKT3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.